Table 2.
Univariate analysis of risk factors for PP‐IFI in pts receiving caspofungin as primary antifungal prophylaxis (PAP)
| Characteristics | HR (95% CI) | P |
|---|---|---|
| Sex | ||
| Female | 1 | 0.7 |
| Male | 0.7 (0.1‐3.1) | |
| Disease type | ||
| Myeloid | 1 | 0.9 |
| Lymphoid | 0.9 (0.2‐3.8) | |
| Disease status before transplant | ||
| CR | 1 | |
| PR | 3.4 (0.8‐13.7) | 0.08 |
| SD/PD | 0 | 0.9 |
| DRI | ||
| LR/IR | 1 | 0.3 |
| HR/VHR | 2.0 (0.5‐8.5) | |
| Sex mismatch | ||
| Others | 1 | 0.6 |
| F→M | 1.5 (0.3‐7.6) | |
| HCT‐CI | ||
| 0‐2 | 1 | 0.3 |
| ≥3 | 1.9 (0.4‐8.3) | |
| Conditioning | ||
| MAC | 1 | |
| RIC | NA | 0.9 |
| NMA | NA | 0.9 |
| Graft type | ||
| BM | 1 | 0.6 |
| PBSC | 0.7 (0.1‐2.8) | |
| CMV serostatus | ||
| Others | 1 | 0.7 |
| Neg/Pos | 1.3 (0.2‐6.8) | |
| Donor type | ||
| Parent | 1 | |
| Sibling | 0.6 (0.05‐6.9) | 0.7 |
| Child | 2.0 (0.2‐17.2) | 0.5 |
| Cousin/Nephew | 0 | 0.9 |
| GITMO early phase | ||
| Standard risk | 1 | 0.6 |
| High Risk | 1.4 (0.2‐7.2) | |
| GITMO late phase | ||
| Low risk | 1 | 0.4 |
| High risk | 0.5 (0.1‐2.6) | |
| aGVHD | ||
| No | 1 | |
| 2‐4 | 0.6(0.1‐3.1) | 0.6 |
| Recipient age | 1.03 (0.98‐1.08) | 0.2 |
| Donor age | 0.96 (0.91‐1.02) | 0.2 |
| Neutropenia | ||
| <=21 Days | 1 | 0.3 |
| >21 Days | 2.06 (0‐49‐8.63) | |
| Neutropenia duration | 1.04 (1.004‐1.09) | 0.03 |
HR, hazard ratio; CI, confident interval; CR, complete remission; PR, partial remission; SD/PD, stable disease/progressive disease; DRI, Disease Risk Index; LR, low risk; IR, intermediate risk; HR, high risk; VHR, very high risk; Tx, transplant; F→M, female donor into male recipient; HCT‐CI, hematopoietic cell transplant‐comorbidity index; NMA, non‐myeloablative conditioning; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; BM, bone marrow; PBSC, peripheral blood stem cells; CMV, cytomegalovirus; aGVHD, acute graft‐versus‐host disease; GITMO, Gruppo Italiano Trapianto Midollo Osseo.
P values < 0.05 are highlighted in bold.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.